Table of Contents Author Guidelines Submit a Manuscript
Tuberculosis Research and Treatment
Volume 2010, Article ID 406346, 6 pages
http://dx.doi.org/10.1155/2010/406346
Clinical Study

The Soluble Plasminogen Activator Receptor as a Biomarker on Monitoring the Therapy Progress of Pulmonary TB-AFB(+) Patients

1Laboratory of Biochemistry-Molecular Biology, Faculty of Medicine, Brawijaya University, Malang 65145, Indonesia
2Department of Pulmonology, Faculty of Medicine, Brawijaya University Malang-Dr. Saiful Anwar Hospital Malang, Malang 65145, Indonesia

Received 29 June 2010; Accepted 8 September 2010

Academic Editor: William N. Rom

Copyright © 2010 Tri Yudani Mardining Raras and Iin Noor Chozin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Jo, K. S. Thomas, L. Wu, and S. L. Gonias, “Soluble Urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct Urokinase-independent effects on cell signaling,” The Journal of Biological Chemistry, vol. 278, no. 47, pp. 46692–46698, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Rabna, A. Andersen, C. Wejse et al., “High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test,” Tropical Medicine and International Health, vol. 14, no. 9, pp. 986–994, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Eugen-Olsen, P. Gustafson, N. Sidenius et al., “The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau,” International Journal of Tuberculosis and Lung Disease, vol. 6, no. 8, pp. 686–692, 2002. View at Google Scholar
  4. J. F. D. Siawaya, M. Ruhwald, J. Eugen-Olsen, and G. Walzl, “Correlates for disease progression and prognosis during concurrent HIV/TB infection,” International Journal of Infectious Diseases, vol. 11, no. 4, pp. 289–299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. PDPI. Perhimpunan Dokter Paru Indonesia, Tuberkulosis : Pedoman Diagnosis dan Penatalaksanaan di Indonesia, Indah Offset Citra Grafika, Jakarta, Indonesia, 2006.
  6. WHO, TB/HIV A Clinical Manual. Stop TB Dept. Dept of HIV/AIDS. Dept Child and Adolescent Health and Development, World Health Organization, Geneva, Switzerland, 2004.
  7. ViroGates. suPARnostic ELISA Kit: Enzyme-linked immunosorbent assay for quantitative determination of soluble urokinase plasminogen activator receptor in human plasma. Copenhagen, Denmark, 2007.
  8. P. F. Barnes and B. Wizel, “Type 1 cytokines and the pathogenesis of tuberculosis,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 6, pp. 1773–1774, 2000. View at Google Scholar · View at Scopus
  9. W. N. Rom and S. M. Garay, Tuberculosis, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2nd edition, 2004.
  10. O. G. Wilhelm, S. Wilhelm, G. M. Escott et al., “Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression,” Journal of Cellular Physiology, vol. 180, no. 2, pp. 225–235, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. R. van Crevel, T. H. M. Ottenhoff, and J. W. M. van der Meer, “Innate immunity to Mycobacterium tuberculosis,” Clinical Microbiology Reviews, vol. 15, no. 2, pp. 294–309, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Alsagaff and A. dan Mukty, Dasar-Dasar Ilmu Penyakit Paru, Airlangga University Press, Surabaya, Indonesia, 2002.
  13. J. F. D. Siawaya, N. B. Bapela, K. Ronacher et al., “Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response,” Journal of Infection, vol. 56, no. 5, pp. 340–347, 2008. View at Publisher · View at Google Scholar · View at Scopus